drugset

drugset / Trial / NCT01128894

A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.

NCT01128894 ↗

Phase 3 Completed 841 enrolled GlaxoSmithKline

RandomizedParallel-groupOpen-labelTreatment

Summary

This open-label study examines the efficacy and safety of albiglutide as compared with liraglutide in subjects with type 2 diabetes.

Timeline

Start: 2010-05
Primary completion: 2011-09
Completion: 2011-09

Publications

Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J; HARMONY 7 study group. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014 Apr;2(4):289-297. doi: 10.1016/S2213-8587(13)70214-6. Epub 2014 Feb 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Liraglutide	Peptide	1.8 mg	Subcutaneous
Subject	albiglutide	Peptide	50 mg	Subcutaneous

Indications